Market Overview

UPDATE: Allergan Upgraded by Citigroup on Strong Fundamentals

Share:
Related AGN
Q3 13F Roundup: How Buffett, Einhorn, Paulson, And Others Adjusted Their Portfolio
The Companies That Manipulated The Tax System, According To The Paradise Papers
Restasis Buyers Hit Allergan With An Anti-Trust Lawsuit (Seeking Alpha)

Tuesday morning rating updates include an upgrade from Citigroup analyst Liav Abraham, boosting Allergen (NYSE: AGN) from Neutral to Buy, with a price rating of $130 from $95.

Citigroup is sold on Allergan's long-term growth with strong balance sheet and cash flow to back up their rating change. The report notes, "Following the recent removal of the Restasis and Lumigan overhangs, the fundamental risk-reward profile of AGN has shifted, in our view, with the stock offering the most attractive organic growth profile amongst the peer group, along with significant balance sheet optionality."

AGN is currently trading up around the $114 mark after closing Monday at $112.26.

Latest Ratings for AGN

DateFirmActionFromTo
Nov 2017Credit SuisseMaintainsOutperform
Nov 2017Morgan StanleyMaintainsEqual-Weight
Oct 2017CitigroupMaintainsBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Citigroup Liav AbrahamUpgrades Price Target Analyst Ratings

 

Related Articles (AGN)

View Comments and Join the Discussion!

Partner Center